Compare RFL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RFL | ANL |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 52.0M |
| IPO Year | N/A | 2023 |
| Metric | RFL | ANL |
|---|---|---|
| Price | $1.23 | $1.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 96.8K | 10.1K |
| Earning Date | 11-19-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.17 | $1.10 |
| 52 Week High | $3.19 | $2.99 |
| Indicator | RFL | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 30.41 |
| Support Level | $1.20 | $1.32 |
| Resistance Level | $1.29 | $1.59 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 41.67 | 0.00 |
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.